Q-omics provides the consensus-scored RAB36 profile across patient tissues and cancer cell-line models. RAB36 expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in KIRP. Among the 18 cancer types available for tumor–normal comparison, RAB36 is differentially expressed in 11, with the highest sampling consensus in COAD. Additionally, RAB36 RNA expression shows 18,676 significant gene co-expression associations, with the highest sampling consensus in KIRP. Together, these results highlight KIRP, and COAD as cancer lineages where RAB36 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for RAB36 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes RAB36 survival associations across molecular data types. RAB36 RNA expression shows survival associations in the most cancer types (23), followed by mutation status (3) and mass-spec protein abundance (9). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible RAB36 RNA expression–survival associations across cancer types. High RAB36 expression shows unfavorable associations in LGG and LAML, but favorable associations in KIRP, HNSC, READ and CESC. The KIRP Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p = .001). Together, the overview and detailed table identify KIRP as the clearest survival context for RAB36 RNA expression.
This table summarizes RAB36 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11, while mass-spec protein shows differences in 6. The strongest signals are observed in KICH for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for RAB36. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. RAB36 shows lower tumor expression in KICH, THCA and LUAD and higher tumor expression in COAD, KIRP and HNSC. The COAD box plot shows higher RAB36 RNA expression in tumor versus normal tissue (log2 FC = +1.925, t-test p < 0.001).
This table shows molecular features associated with RAB36 in patient tissues and cancer cell lines. In patient samples, RAB36 shows the broadest associations at the RNA and protein expression levels, with KIRP recurring as the lineage with the largest associated feature set. In cancer cell lines, RAB36 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BLOOD_Leukemia, while CRISPR and shRNA rows add functional-dependency signals in LUNG_NSCLC_LUAD and CNS.
